JP2020534313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534313A5 JP2020534313A5 JP2020516552A JP2020516552A JP2020534313A5 JP 2020534313 A5 JP2020534313 A5 JP 2020534313A5 JP 2020516552 A JP2020516552 A JP 2020516552A JP 2020516552 A JP2020516552 A JP 2020516552A JP 2020534313 A5 JP2020534313 A5 JP 2020534313A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell composition
- composition according
- isolated cell
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561044P | 2017-09-20 | 2017-09-20 | |
| US62/561,044 | 2017-09-20 | ||
| US201862656679P | 2018-04-12 | 2018-04-12 | |
| US62/656,679 | 2018-04-12 | ||
| PCT/US2018/051971 WO2019060558A1 (en) | 2017-09-20 | 2018-09-20 | CELLULAR COMPOSITIONS COMPRISING ANTIGEN-SPECIFIC T CELLS FOR ADOPTIVE THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534313A JP2020534313A (ja) | 2020-11-26 |
| JP2020534313A5 true JP2020534313A5 (https=) | 2021-10-14 |
| JP7475684B2 JP7475684B2 (ja) | 2024-04-30 |
Family
ID=65810886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516552A Active JP7475684B2 (ja) | 2017-09-20 | 2018-09-20 | 養子療法のための抗原特異的ｔ細胞を含む細胞組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190119639A1 (https=) |
| EP (1) | EP3684402A4 (https=) |
| JP (1) | JP7475684B2 (https=) |
| KR (1) | KR102850471B1 (https=) |
| CN (1) | CN111629748A (https=) |
| AU (1) | AU2018337960B2 (https=) |
| BR (1) | BR112020005552A2 (https=) |
| CA (1) | CA3076490A1 (https=) |
| IL (1) | IL273452B2 (https=) |
| MX (1) | MX2020003129A (https=) |
| RU (1) | RU2020113627A (https=) |
| SG (1) | SG11202002523YA (https=) |
| WO (1) | WO2019060558A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006065495A2 (en) | 2004-11-24 | 2006-06-22 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| CA3081840A1 (en) | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| CA3122131A1 (en) * | 2018-09-21 | 2020-03-26 | Zonghai Li | Method for gene editing of cell on the basis of crispr/cas system |
| AU2019375997A1 (en) * | 2018-11-08 | 2021-06-03 | Neximmune, Inc. | T cell compositions with improved phenotypic properties |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| US20240368545A1 (en) * | 2021-05-07 | 2024-11-07 | Yasuhito TOKUMOTO | Manufacturing method of memory t cells |
| CN113945715B (zh) * | 2021-08-30 | 2023-04-21 | 四川大学华西医院 | 供者特异性IL-21和IFN-γ的检测方法及应用 |
| WO2023159088A1 (en) * | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| US20050169898A1 (en) * | 1997-04-15 | 2005-08-04 | Jianlin Gong | Cell fusions and methods of making and using the same |
| US8748405B2 (en) * | 2007-01-26 | 2014-06-10 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| AU2012305931B2 (en) | 2011-09-08 | 2017-09-07 | Yeda Research And Development Co. Ltd | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| KR102453188B1 (ko) | 2013-06-24 | 2022-10-07 | 넥스이뮨, 인크. | 면역요법을 위한 조성물 및 방법 |
| CN107002038B (zh) * | 2014-09-17 | 2021-10-15 | 约翰·霍普金斯大学 | 用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法 |
| EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| SG11201705064XA (en) | 2014-12-24 | 2017-07-28 | Neximmune Inc | Nanoparticle compositions and methods for immunotherapy |
| CN106714836A (zh) * | 2015-06-05 | 2017-05-24 | H·李·莫菲特癌症中心研究有限公司 | Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗 |
| US9790467B2 (en) * | 2015-09-22 | 2017-10-17 | Qt Holdings Corp | Methods and compositions for activation or expansion of T lymphocytes |
| MX2018005618A (es) * | 2015-11-05 | 2018-08-01 | Juno Therapeutics Inc | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. |
| SG11201804648RA (en) * | 2015-12-04 | 2018-06-28 | Univ Texas | Slc45a2 peptides for immunotherapy |
| TW201621210A (zh) * | 2016-02-26 | 2016-06-16 | 液光固態照明股份有限公司 | 發光二極體光源及燈具 |
| RU2021107053A (ru) * | 2016-03-16 | 2021-08-24 | Нексиммьюн, Инк. | Получение антигенспецифических t-клеток |
-
2018
- 2018-09-20 AU AU2018337960A patent/AU2018337960B2/en active Active
- 2018-09-20 RU RU2020113627A patent/RU2020113627A/ru unknown
- 2018-09-20 WO PCT/US2018/051971 patent/WO2019060558A1/en not_active Ceased
- 2018-09-20 SG SG11202002523YA patent/SG11202002523YA/en unknown
- 2018-09-20 IL IL273452A patent/IL273452B2/en unknown
- 2018-09-20 EP EP18859009.5A patent/EP3684402A4/en active Pending
- 2018-09-20 JP JP2020516552A patent/JP7475684B2/ja active Active
- 2018-09-20 MX MX2020003129A patent/MX2020003129A/es unknown
- 2018-09-20 KR KR1020207011215A patent/KR102850471B1/ko active Active
- 2018-09-20 CN CN201880074419.8A patent/CN111629748A/zh active Pending
- 2018-09-20 CA CA3076490A patent/CA3076490A1/en active Pending
- 2018-09-20 US US16/136,931 patent/US20190119639A1/en not_active Abandoned
- 2018-09-20 BR BR112020005552-2A patent/BR112020005552A2/pt unknown
-
2022
- 2022-11-18 US US17/989,905 patent/US20230399613A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534313A5 (https=) | ||
| Butler et al. | Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell | |
| RU2020113627A (ru) | Композиции клеток, содержащие антигенспецифические т-клетки, для адоптивной терапии | |
| Hwang et al. | Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control | |
| Baxevanis et al. | Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor | |
| AU2015311761B2 (en) | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions | |
| Kalinski et al. | Dendritic cell-based therapeutic cancer vaccines: what we have and what we need | |
| US11027001B2 (en) | Therapeutic cancer vaccines derived from a novel dendritic cell line | |
| JP6522671B2 (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| Ye et al. | Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes | |
| Lee et al. | Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia | |
| Ferlazzo et al. | Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-α are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells | |
| US20160208216A1 (en) | Methods of cell culture for adoptive cell therapy | |
| Khan et al. | Expanded human blood-derived γδT cells display potent antigen-presentation functions | |
| CN120536375A (zh) | 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物 | |
| Willemen et al. | Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions | |
| CN102618498A (zh) | Hla-a0201限制性抗原特异性ctl制备方法 | |
| Salgaller et al. | Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide | |
| KR20210095157A (ko) | 개선된 표현형 속성을 갖는 t 세포 조성물 | |
| Wu et al. | CD19 chimeric antigen receptor–redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide–derived dendritic cell vaccine in leukemia | |
| Kayser et al. | Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy | |
| Zhang et al. | Generation of mouse pluripotent stem cell–derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells | |
| CN117580946A (zh) | 用于产生抗原特异性t细胞的方法 | |
| Chevaleyre et al. | The tumor antigen cyclin B1 hosts multiple CD4 T cell epitopes differently recognized by pre-existing naive and memory cells in both healthy and cancer donors | |
| WO2019217512A1 (en) | Compositions and methods for culturing and expanding cells |